CAJ | 학술논문

目的：通过观察派能达胶囊对慢乙肝肝硬化患者外周血象及症状的影响，探讨其是否可增强抗病毒治疗疗效，为临床慢乙肝肝硬化的治疗提供帮助。方法60例患者随机分为2组，每组30例，对照组用抗病毒药（拉米夫定100mg/d+阿德福韦酯10mg/d），治疗组加用派能达胶囊（2粒/次，2次/d）；派能达胶囊治疗6个月，治疗结束后所有患者继续服用抗病毒药物并随访。比较两组治疗前后的中医证候积分。对病例中伴白细胞减少（<4*109/L）和（或）血小板减少（<100*109/L）的比较治疗前后血细胞水平。结果1.治疗后，治疗组患者的WBC计数较治疗前升高（P<0.05），对照组患者的WBC计数较治疗前也升高（P>0.05），治疗后治疗组的WBC计数高于对照组（P<0.05）；2.治疗后2组血小板计数较前均有升高，但同组治疗前后比较无统计学差异，两组间比较治疗前后PLT计数也无统计学差异；3.2组治疗后证候积分均下降（P<0.05），且治疗后治疗组积分低于对照组（P<0.05）。结论派能达胶囊联合抗病毒治疗可提高抗病毒疗效，改善慢乙肝肝硬化患者血细胞减少症，改善患者临床症状，提高生活质量。
목적：통과관찰파능체효낭대만을간간경화환자외주혈상급증상적영향，탐토기시부가증강항병독치료료효，위림상만을간간경화적치료제공방조。방법60례환자수궤분위2조，매조30례，대조조용항병독약（랍미부정100mg/d+아덕복위지10mg/d），치료조가용파능체효낭（2립/차，2차/d）；파능체효낭치료6개월，치료결속후소유환자계속복용항병독약물병수방。비교량조치료전후적중의증후적분。대병례중반백세포감소（<4*109/L）화（혹）혈소판감소（<100*109/L）적비교치료전후혈세포수평。결과1.치료후，치료조환자적WBC계수교치료전승고（P<0.05），대조조환자적WBC계수교치료전야승고（P>0.05），치료후치료조적WBC계수고우대조조（P<0.05）；2.치료후2조혈소판계수교전균유승고，단동조치료전후비교무통계학차이，량조간비교치료전후PLT계수야무통계학차이；3.2조치료후증후적분균하강（P<0.05），차치료후치료조적분저우대조조（P<0.05）。결론파능체효낭연합항병독치료가제고항병독료효，개선만을간간경화환자혈세포감소증，개선환자림상증상，제고생활질량。
Objective To observe the effect of Painengda on peripheral blood cell count and symptoms of patients with Chronic Hepatitis B and Liver fibrosis,explore whether can it strengthen the curative effect of nucleoside analogues,and help in treatment of Chronic Hepatitis B and Liver fibrosis. Methods The selected 60 patients were randomly assigned to two Groups(30 patients in each group),the control group were treated by nucleoside analogues(Lamivudine 100mg and Adefovir 10mg once a day) while the treated group were treated by nucleoside analogues(the same as the control group)and Painengda,which dose was 2 pills twice a day. After 6 months,the treatment of Painengda was stopped,the treatment of nucleoside analogues going on in both of the groups. Then compared syndrome integral of two groups and compared the peripheral blood cell count of patients with low level of WBC (<4 × 109/L)and(or)PLT(<100 × 109/L). Results 1. The WBC level in the treated group was obviously enhanced than in the control group(P<0.05);2. The PLT level raised in each group after therapy,but there were no statistical differences in each group itself or between the two groups;3. The syndrome integral decreased in both of the two groups after treatment(P<0.05),while the treated group ’s lower(P<0.05). Conclusion Painengda can improve the curative effect of nucleoside analogues,increase the count of WBC and PLT and improve the clinical symptoms,creating a better quality of life.